# Amerisafe Inc: financial statements, quarterly

AMSF · Nasdaq · CIK 1018979 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/amsf.md) · [Financials](/companies/amsf/financials.md) · [Filings](/companies/amsf/filings.md) · [Insiders](/companies/amsf/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/amsf/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [72.6](/filings/0000950170-24-117414.md) | [80.1 d](/filings/0001193125-26-082513.md) | [80.5](/filings/0000950170-25-061007.md) | [75.8](/filings/0000950170-25-098775.md) | [78.7](/filings/0001193125-25-258532.md) | [74.0 d](/filings/0001193125-26-082513.md) | [72.6](/filings/0001193125-26-173630.md) | [81.1](/filings/0001193125-26-314074.md) | [82.0](/filings/0001193125-25-258532.md) | [81.6 d](/filings/0001193125-26-082513.md) | [80.1](/filings/0001193125-26-173630.md) | [92.0](/filings/0001193125-26-314074.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [2.4](/filings/0000950170-24-117414.md) | [4.8 d](/filings/0001193125-26-082513.md) | [3.8](/filings/0000950170-25-061007.md) | [2.8](/filings/0000950170-25-098775.md) | [3.5](/filings/0001193125-25-258532.md) | [3.6 d](/filings/0001193125-26-082513.md) | [2.3](/filings/0001193125-26-173630.md) | [3.5](/filings/0001193125-26-314074.md) | [3.7](/filings/0001193125-25-258532.md) | [2.3 d](/filings/0001193125-26-082513.md) | [2.0](/filings/0001193125-26-173630.md) | [3.7](/filings/0001193125-26-314074.md) |
| Net income | $m | [10.0](/filings/0000950170-24-117414.md) | [19.2 d](/filings/0001193125-26-082513.md) | [16.9](/filings/0000950170-25-061007.md) | [11.0](/filings/0000950170-25-098775.md) | [14.3](/filings/0001193125-25-258532.md) | [13.2 d](/filings/0001193125-26-082513.md) | [8.9](/filings/0001193125-26-173630.md) | [14.0](/filings/0001193125-26-314074.md) | [13.8](/filings/0001193125-25-258532.md) | [10.4 d](/filings/0001193125-26-082513.md) | [8.1](/filings/0001193125-26-173630.md) | [14.6](/filings/0001193125-26-314074.md) |
| Diluted EPS | $ per share | [0.52](/filings/0000950170-24-117414.md) | not reported | [0.88](/filings/0000950170-25-061007.md) | [0.57](/filings/0000950170-25-098775.md) | [0.75](/filings/0001193125-25-258532.md) | not reported | [0.47](/filings/0001193125-26-173630.md) | [0.73](/filings/0001193125-26-314074.md) | [0.72](/filings/0001193125-25-258532.md) | not reported | [0.43](/filings/0001193125-26-173630.md) | [0.78](/filings/0001193125-26-314074.md) |
| Basic EPS | $ per share | [0.52](/filings/0000950170-24-117414.md) | not reported | [0.89](/filings/0000950170-25-061007.md) | [0.58](/filings/0000950170-25-098775.md) | [0.75](/filings/0001193125-25-258532.md) | not reported | [0.47](/filings/0001193125-26-173630.md) | [0.73](/filings/0001193125-26-314074.md) | [0.73](/filings/0001193125-25-258532.md) | not reported | [0.43](/filings/0001193125-26-173630.md) | [0.79](/filings/0001193125-26-314074.md) |

- Revenue: us-gaap:Revenues
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [59.2](/filings/0000950170-23-055974.md) | [38.7](/filings/0000950170-25-030059.md) | [33.4](/filings/0000950170-24-049070.md) | [30.6](/filings/0000950170-24-087848.md) | [63.7](/filings/0000950170-24-117414.md) | [44.0](/filings/0001193125-26-082513.md) | [44.8](/filings/0000950170-25-061007.md) | [48.5](/filings/0000950170-25-098775.md) | [54.7](/filings/0001193125-25-258532.md) | [61.9](/filings/0001193125-26-314074.md) | [34.2](/filings/0001193125-26-173630.md) | [65.5](/filings/0001193125-26-314074.md) |
| Total assets | $m | [1,297](/filings/0000950170-23-055974.md) | [1,229](/filings/0000950170-25-030059.md) | [1,243](/filings/0000950170-24-049070.md) | [1,234](/filings/0000950170-24-087848.md) | [1,255](/filings/0000950170-24-117414.md) | [1,158](/filings/0001193125-26-082513.md) | [1,157](/filings/0000950170-25-061007.md) | [1,155](/filings/0000950170-25-098775.md) | [1,165](/filings/0001193125-25-258532.md) | [1,131](/filings/0001193125-26-314074.md) | [1,123](/filings/0001193125-26-173630.md) | [1,127](/filings/0001193125-26-314074.md) |
| Total liabilities | $m | [961](/filings/0000950170-23-055974.md) | [937](/filings/0000950170-25-030059.md) | [942](/filings/0000950170-24-049070.md) | [933](/filings/0000950170-24-087848.md) | [940](/filings/0000950170-24-117414.md) | [900](/filings/0001193125-26-082513.md) | [896](/filings/0000950170-25-061007.md) | [890](/filings/0000950170-25-098775.md) | [890](/filings/0001193125-25-258532.md) | [879](/filings/0001193125-26-314074.md) | [876](/filings/0001193125-26-173630.md) | [877](/filings/0001193125-26-314074.md) |
| Shareholders' equity | $m | [336](/filings/0000950170-24-117414.md) | [292](/filings/0001193125-26-082513.md) | [301](/filings/0000950170-25-098775.md) | [301](/filings/0001193125-25-258532.md) | [314](/filings/0001193125-25-258532.md) | [257](/filings/0001193125-26-314074.md) | [261](/filings/0001193125-26-314074.md) | [266](/filings/0001193125-26-314074.md) | [275](/filings/0001193125-25-258532.md) | [252](/filings/0001193125-26-314074.md) | [247](/filings/0001193125-26-314074.md) | [250](/filings/0001193125-26-314074.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [5.1 d](/filings/0000950170-24-117414.md) | [4.0 d](/filings/0001193125-26-082513.md) | [7.5](/filings/0000950170-25-061007.md) | [(2.6) d](/filings/0000950170-25-098775.md) | [8.4 d](/filings/0001193125-25-258532.md) | [10.8 d](/filings/0001193125-26-082513.md) | [(1.8)](/filings/0001193125-26-173630.md) | [(8.4) d](/filings/0001193125-26-314074.md) | [10.7 d](/filings/0001193125-25-258532.md) | [10.6 d](/filings/0001193125-26-082513.md) | [(2.7)](/filings/0001193125-26-173630.md) | [1.8 d](/filings/0001193125-26-314074.md) |
| Capital expenditure | $m | [0.5 d](/filings/0000950170-24-117414.md) | [0.0 d](/filings/0001193125-26-082513.md) | [0.7](/filings/0000950170-25-061007.md) | [0.1 d](/filings/0000950170-25-098775.md) | [0.0 d](/filings/0001193125-25-258532.md) | [0.0 d](/filings/0001193125-26-082513.md) | [0.0](/filings/0001193125-26-173630.md) | [1.1 d](/filings/0001193125-26-314074.md) | [0.9 d](/filings/0001193125-25-258532.md) | [0.2 d](/filings/0001193125-26-082513.md) | [0.0](/filings/0001193125-26-173630.md) | [0.0 d](/filings/0001193125-26-314074.md) |
| Dividends paid | $m | [6.6 d](/filings/0000950170-24-117414.md) | [73.6 d](/filings/0001193125-26-082513.md) | [7.1](/filings/0000950170-25-061007.md) | [7.1 d](/filings/0000950170-25-098775.md) | [7.1 d](/filings/0001193125-25-258532.md) | [64.2 d](/filings/0001193125-26-082513.md) | [7.4](/filings/0001193125-26-173630.md) | [7.5 d](/filings/0001193125-26-314074.md) | [7.5 d](/filings/0001193125-25-258532.md) | [26.2 d](/filings/0001193125-26-082513.md) | [7.8](/filings/0001193125-26-173630.md) | [7.6 d](/filings/0001193125-26-314074.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [19.3](/filings/0000950170-23-055974.md) | [19.2](/filings/0000950170-24-049070.md) | [19.2](/filings/0000950170-24-087848.md) | [19.2](/filings/0000950170-24-117414.md) | [19.2](/filings/0000950170-25-061007.md) | [19.1](/filings/0000950170-25-098775.md) | [19.1](/filings/0001193125-25-258532.md) | [19.2](/filings/0001193125-26-173630.md) | [19.1](/filings/0001193125-26-314074.md) | [19.1](/filings/0001193125-25-258532.md) | [18.9](/filings/0001193125-26-173630.md) | [18.7](/filings/0001193125-26-314074.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 18,536,058 at 2026-07-17, from the cover of the [10-Q filed 2026-07-23](/filings/0001193125-26-314074.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.